Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Histologic grading of meningiomas has prognostic and clinical therapeutic implications. Meningiomas were histologically classified into 3 different World Health Organization grades. Grade II, an atypical meningioma, was defined by major and various minor histologic criteria. However, these histologic criteria sometimes are not fulfilled, and other criteria are necessary. We studied and analyzed the immunohistochemical expression of MIB-1, p53, p21WAF1, p27KIP1 proteins in 146 cases of meningiomas, including 109 benign, 27 atypical, and 10 anaplastic meningiomas. Most of the benign meningiomas expressed low MIB-1 labeling index (mean, 1.5%), and fewer cases had p53 protein expression. In contrast, the anaplastic meningiomas had a high labeling index of MIB-1 (mean, 19.5%) and always expressed p53 protein, with a mean labeling index of 6.3%. The atypical meningiomas had MIB-1 and p53 labeling indexes in the range between benign and anaplastic meningiomas, with mean labeling indexes of 8.1% and 3.5%, respectively. These expressions were statistically significant among benign, atypical, and anaplastic meningiomas (P <.001). We conclude that the immunohistochemistry of MIB-1 and p53 protein will be valuable in discriminating atypical meningiomas from benign or anaplastic meningiomas, at least in histologically borderline cases. In addition, we also found direct correlation of p21 and inverse correlation of p27 expressions in meningiomas with increasing histologic grade and proliferative index.
Amatya
V J
VJ
Second Department of Pathology, Hiroshima University School of Medicine, Hiroshima, Japan.
Takeshima
Y
Y
Sugiyama
K
K
Kurisu
K
K
Nishisaka
T
T
Fukuhara
T
T
Inai
K
K
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000032:analysis / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000032:analysis / Q000378:metabolism*; D008297:Male; D008577:Meningeal Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D008579:Meningioma / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D008840:Microfilament Proteins / Q000032:analysis / Q000378:metabolism*; D008875:Middle Aged; D009124:Muscle Proteins; D009363:Neoplasm Proteins / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000378:metabolism*
D014408:Biomarkers, Tumor; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D019394:Ki-67 Antigen; D008840:Microfilament Proteins; D009124:Muscle Proteins; D009363:Neoplasm Proteins; C058992:Tagln protein, mouse; D016159:Tumor Suppressor Protein p53